GO:0043540 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex: Components, Assembly and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0043540 describes the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex, a bifunctional homodimeric enzyme that controls fructose 2,6-bisphosphate levels.
• The complex is encoded by the PFKFB gene family (PFKFB1-4), with tissue-specific isoforms that differ in kinase-to-phosphatase activity ratios.
• Fructose 2,6-bisphosphate is a potent allosteric activator of PFK-1 and inhibitor of fructose-1,6-bisphosphatase, linking the complex to both glycolysis and gluconeogenesis.
• PFKFB3 and PFKFB4 are frequently upregulated in cancers and support tumor growth, survival, and metabolic adaptation.
• The complex is regulated by signaling pathways including mTORC1, JAK/STAT, and estrogen receptor pathways, making it a node for therapeutic intervention.
• CRISPR-based knockout, point mutation, knock-in, and overexpression models enable precise dissection of PFKFB isoform function in health and disease.
Description
The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex (GO:0043540) is a bifunctional enzyme complex that catalyzes both the synthesis and degradation of fructose 2,6-bisphosphate, a key allosteric regulator of glycolysis and gluconeogenesis. This complex is a homodimer, with each subunit containing an N-terminal 6-phosphofructo-2-kinase domain and a C-terminal fructose-2,6-biphosphatase domain. The balance between these two activities determines the cellular concentration of fructose 2,6-bisphosphate, which in turn modulates the activity of phosphofructokinase-1 (PFK-1) and fructose-1,6-bisphosphatase, the rate-limiting enzymes of glycolysis and gluconeogenesis, respectively. Researchers study GO:0043540 because it sits at the crossroads of glucose metabolism and is implicated in cancer, metabolic disorders, and immune cell function. The four PFKFB isoforms (PFKFB1-4) exhibit distinct tissue distribution and kinetic properties, enabling fine-tuned regulation of glycolytic flux in different physiological contexts. For example, PFKFB3 is a pro-glycolytic isoform that is upregulated in many tumors and is required for tumor growth in tuberous sclerosis complex. PFKFB4, on the other hand, has been identified as a survival factor in prostate cancer. Understanding the composition, regulation, and function of this complex is essential for developing targeted therapies that exploit metabolic vulnerabilities in cancer and other diseases. This article provides a comprehensive overview of GO:0043540, including its definition, structure, key genes, regulatory mechanisms, disease associations, and research methods, with a focus on CRISPR-based approaches for functional studies.
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex At A Glance
| GO ID | GO:0043540 |
|---|---|
| GO term | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex |
| Ontology | cellular_component |
| Synonym | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 1 complex, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 complex, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 complex, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 complex |
| Major function | Bifunctional enzyme complex that synthesizes and degrades fructose 2,6-bisphosphate, regulating glycolysis and gluconeogenesis |
| Cellular location | Cytosol |
| Subunit composition | Homodimer |
| Enzymatic activities | 6-phosphofructo-2-kinase and fructose-2,6-biphosphatase |
| Key regulator | Fructose 2,6-bisphosphate |
| Associated genes | PFKFB1, PFKFB2, PFKFB3, PFKFB4 |
What Is GO:0043540?
GO:0043540 refers to a homodimeric, bifunctional enzyme complex that catalyzes the synthesis and degradation of fructose 2,6-bisphosphate. This complex is required for both glycolysis and gluconeogenesis, as fructose 2,6-bisphosphate acts as a potent allosteric activator of phosphofructokinase-1 and an inhibitor of fructose-1,6-bisphosphatase. The complex is composed of two identical subunits, each containing a 6-phosphofructo-2-kinase domain and a fructose-2,6-biphosphatase domain, allowing it to both produce and break down fructose 2,6-bisphosphate in response to metabolic signals.
Why Is 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex Important in Cell Biology?
The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex is critically important because it controls the cellular levels of fructose 2,6-bisphosphate, a master regulator of glycolytic flux. By balancing the synthesis and degradation of this metabolite, the complex determines whether glucose is directed toward energy production (glycolysis) or glucose synthesis (gluconeogenesis). This regulatory role makes it essential for maintaining glucose homeostasis in tissues such as liver, muscle, and brain. Dysregulation of the complex is linked to cancer, where isoforms like PFKFB3 and PFKFB4 support tumor growth and survival by promoting aerobic glycolysis (the Warburg effect). In immune cells, PFKFB3 is upregulated by mTORC1 and is required for tumor growth in tuberous sclerosis complex. Additionally, the complex is implicated in rheumatoid arthritis, where JAK/STAT blockade alters synovial bioenergetics and mitochondrial function. Therefore, understanding GO:0043540 provides insights into metabolic reprogramming in disease and offers opportunities for therapeutic targeting.
• Regulates glycolysis and gluconeogenesis through fructose 2,6-bisphosphate.
• PFKFB3 is upregulated by mTORC1 and is critical for tumor growth in tuberous sclerosis complex.
• PFKFB4 is an important regulator of prostate cancer cell survival.
• The complex is a target of JAK/STAT signaling in rheumatoid arthritis, affecting synovial bioenergetics.
• Estrogen receptor pathways interact with PFKFB isoforms in vascular immune interfaces.
• PFKFB3 shRNA-loaded liposomes enhance the efficacy of docetaxel in non-small cell lung cancer.
• The complex is involved in cell cycle progression control by APC and SCF during G1-to-S transition.
• Isoform-specific functions make it a promising target for precision medicine.
• CRISPR screens can identify context-dependent dependencies on PFKFB genes.
• The complex links metabolic state to immune responses, as seen in antiviral innate immunity.
What Happens During 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
Synthesis of Fructose 2,6-Bisphosphate
In simple terms: The complex makes a molecule that tells cells to burn sugar.
The 6-phosphofructo-2-kinase domain of the complex catalyzes the phosphorylation of fructose 6-phosphate to fructose 2,6-bisphosphate, using ATP as a phosphate donor. This reaction produces fructose 2,6-bisphosphate, which acts as a potent allosteric activator of phosphofructokinase-1 (PFK-1), thereby promoting glycolysis. The kinase activity is regulated by various signals, including hormones and metabolites, to match glycolytic flux with cellular energy demands.
Degradation of Fructose 2,6-Bisphosphate
In simple terms: The complex also breaks down that molecule to slow down sugar burning.
The fructose-2,6-biphosphatase domain of the complex hydrolyzes fructose 2,6-bisphosphate to fructose 6-phosphate and inorganic phosphate. This reaction reduces the cellular level of fructose 2,6-bisphosphate, relieving the activation of PFK-1 and the inhibition of fructose-1,6-bisphosphatase, thereby favoring gluconeogenesis. The balance between kinase and phosphatase activities determines the net effect on glycolytic flux and is tightly regulated by post-translational modifications and allosteric effectors.
Regulation of Glycolysis and Gluconeogenesis
In simple terms: The complex acts like a switch between burning sugar and making sugar.
By controlling fructose 2,6-bisphosphate levels, the complex coordinates the opposing pathways of glycolysis and gluconeogenesis. When fructose 2,6-bisphosphate is high, glycolysis is favored; when low, gluconeogenesis is favored. This regulation is critical for maintaining blood glucose levels, especially in liver and kidney. Isoform-specific expression and regulation allow different tissues to adapt to metabolic demands.
Integration with Cellular Signaling
In simple terms: The complex listens to signals from inside and outside the cell.
The activity of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex is modulated by signaling pathways such as mTORC1, which upregulates PFKFB3 expression to support tumor growth. JAK/STAT blockade alters synovial bioenergetics and mitochondrial function, partly through effects on PFKFB3. Estrogen receptor pathways also interact with PFKFB isoforms in vascular immune interfaces. These signaling inputs allow the complex to integrate metabolic and immune signals.
Key Genes Involved in GO:0043540 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex
The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex is encoded by the PFKFB gene family, which includes four isoforms with distinct tissue distribution and kinetic properties.
| Gene | Major Role | Research Relevance |
|---|---|---|
| PFKFB1 | Liver and muscle isoform; primarily phosphatase activity; regulates gluconeogenesis | Studied in metabolic disorders and glucose homeostasis |
| PFKFB2 | Heart isoform; kinase-dominant; supports glycolysis in cardiac tissue | Investigated in cardiac metabolism and ischemia |
| PFKFB3 | Pro-glycolytic isoform; high kinase activity; induced by hypoxia and mTORC1 | Oncogene in multiple cancers; target for tumor growth inhibition |
| PFKFB4 | Testis and cancer isoform; balanced kinase/phosphatase; supports survival | Regulator of prostate cancer cell survival; potential therapeutic target |
| mTORC1 | Upstream regulator; hyperactivation increases PFKFB3 expression | Critical for tumor growth in tuberous sclerosis complex |
| JAK/STAT | Signaling pathway; blockade alters PFKFB3 and synovial bioenergetics | Therapeutic target in rheumatoid arthritis |
| Estrogen receptor | Hormone receptor; modulates PFKFB expression in vascular immune cells | Implications for vascular inflammation and cancer |
| APC/SCF | E3 ubiquitin ligase complex; controls cell cycle and glucose metabolism | Links PFKFB to G1-to-S transition |
| MAVS-TRAF3/6 | Antiviral innate immunity axis; FZR1 m6A modification affects it | Indirect link to metabolic regulation |
| PFK-1 | Phosphofructokinase-1; activated by fructose 2,6-bisphosphate | Key glycolytic enzyme downstream of PFKFB |
| FBPase | Fructose-1,6-bisphosphatase; inhibited by fructose 2,6-bisphosphate | Gluconeogenic enzyme downstream of PFKFB |
| HIF-1α | Hypoxia-inducible factor; induces PFKFB3 expression | Drives glycolytic phenotype in cancer |
| AMPK | Energy sensor; may regulate PFKFB activity | Links metabolic stress to PFKFB function |
| PKA | Protein kinase A; phosphorylates PFKFB isoforms | Hormonal regulation of glycolysis/gluconeogenesis |
| PKC | Protein kinase C; modulates PFKFB3 activity | Signaling in cancer and immune cells |
| FZR1 | Cell cycle regulator; m6A modification affects antiviral immunity | Potential cross-talk with metabolic pathways |
| TSC1/TSC2 | Tumor suppressors; loss leads to mTORC1 hyperactivation and PFKFB3 upregulation | Model for tuberous sclerosis complex |
| Docetaxel | Chemotherapeutic; combined with PFKFB3 shRNA for lung cancer | Therapeutic strategy targeting PFKFB3 |
How Is 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex Regulated?
The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex is regulated at multiple levels. Transcriptional regulation includes induction of PFKFB3 by hypoxia-inducible factor 1-alpha (HIF-1α) and mTORC1 signaling. Post-translational modifications, such as phosphorylation by protein kinase A (PKA) and AMP-activated protein kinase (AMPK), modulate the kinase-to-phosphatase activity ratio. Allosteric regulation by fructose 6-phosphate and citrate also influences enzyme activity. In rheumatoid arthritis, JAK/STAT blockade alters PFKFB3 expression and synovial bioenergetics. Estrogen receptor signaling can also affect PFKFB isoforms in vascular immune interfaces. These regulatory mechanisms ensure that the complex responds to hormonal, metabolic, and immune signals to maintain energy homeostasis.
6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| PFKFB3 | Tuberous sclerosis complex, non-small cell lung cancer | TSC1/TSC2 knockout cells; xenograft models with PFKFB3 shRNA |
| PFKFB4 | Prostate cancer | PFKFB4 knockout prostate cancer cell lines; survival assays |
| PFKFB1 | Metabolic disorders, glycogen storage disease | Liver-specific PFKFB1 knockout mice; glucose tolerance tests |
| PFKFB3 | Rheumatoid arthritis | Synovial fibroblasts treated with JAK inhibitors; metabolic assays |
| PFKFB2 | Cardiac ischemia | Cardiomyocyte-specific PFKFB2 knockout mice; ischemia-reperfusion models |
Cancer
PFKFB3 and PFKFB4 are frequently upregulated in various cancers and support tumor growth by promoting aerobic glycolysis. In tuberous sclerosis complex, hyperactivated mTORC1 upregulates PFKFB3, which is critical for tumor growth. PFKFB4 is an important regulator of prostate cancer cell survival, and its inhibition reduces tumor growth. In non-small cell lung cancer, PFKFB3 shRNA delivered by liposomes enhances the efficacy of docetaxel. These findings highlight the complex as a therapeutic target in oncology.
Metabolic Disorders
Dysregulation of the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex can lead to metabolic disorders such as diabetes and obesity, as it controls glucose homeostasis. PFKFB1 mutations are associated with glycogen storage disease and hyperinsulinism. Targeting specific isoforms may offer therapeutic benefits for metabolic diseases.
Rheumatoid Arthritis
JAK/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in rheumatoid arthritis, partly through effects on PFKFB3. This suggests that the complex contributes to the metabolic reprogramming of synovial cells in autoimmune arthritis.
Vascular Inflammation
Estrogen receptor functions and pathways at the vascular immune interface involve PFKFB isoforms, linking the complex to vascular inflammation and immune cell metabolism. Further research may reveal therapeutic opportunities for vascular diseases.
From 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does PFKFB3 knockout reduce tumor growth? | PFKFB3 knockout cancer cell lines and xenografts |
| What is the effect of PFKFB4 loss on prostate cancer survival? | PFKFB4 knockout prostate cancer cells; apoptosis assays |
| Can a point mutation in PFKFB3 alter its kinase activity? | CRISPR knock-in of point mutations in PFKFB3 |
| How does PFKFB3 overexpression affect glycolytic flux? | PFKFB3 overexpression in cell lines; Seahorse assays |
| Does tagged PFKFB4 interact with survival proteins? | Knock-in of epitope-tagged PFKFB4; immunoprecipitation |
| What is the role of PFKFB1 in gluconeogenesis? | Liver-specific PFKFB1 knockout mice; metabolic flux analysis |
How to Study the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Seahorse assay | Glycolysis and oxidative phosphorylation | Assess metabolic phenotype of PFKFB knockout cells |
| RNA-seq | Gene expression and splicing | Quantify PFKFB isoforms and identify regulators |
| Immunoprecipitation | Protein-protein interactions | Identify PFKFB complex partners |
| CRISPR screen | Gene essentiality and synthetic lethality | Discover genes interacting with PFKFB |
| Western blot | Protein expression and phosphorylation | Validate PFKFB isoform levels and modifications |
| qRT-PCR | mRNA levels | Measure PFKFB transcript abundance |
| Metabolite profiling | Fructose 2,6-bisphosphate levels | Directly measure complex activity |
| Liposome delivery | Targeted shRNA delivery | Therapeutic knockdown of PFKFB3 in tumors |
Metabolic Flux Analysis
Metabolic flux analysis using Seahorse extracellular flux analyzers measures glycolysis and oxidative phosphorylation in real-time. This method is used to assess the impact of PFKFB knockout or overexpression on cellular metabolism.
RNA Sequencing (RNA-seq)
RNA-seq can quantify PFKFB isoform expression and identify splicing variants. It is used to study transcriptional regulation of PFKFB genes in response to signals like mTORC1.
Proteomics and Immunoprecipitation
Proteomics and immunoprecipitation coupled with mass spectrometry can identify interacting partners of the PFKFB complex and post-translational modifications. These methods help elucidate the complex's regulation.
CRISPR Library Screening
Genome-wide CRISPR knockout screens can identify genes that are synthetic lethal with PFKFB loss or that modulate sensitivity to PFKFB inhibitors. This approach is powerful for discovering context-dependent dependencies.
How CRISPR Can Be Used to Study GO:0043540 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex
Knockout
CRISPR knockout of PFKFB genes is used to study their loss-of-function phenotypes. For example, PFKFB3 knockout reduces tumor growth in tuberous sclerosis complex models, and PFKFB4 knockout decreases prostate cancer cell survival. Knockout cell lines are valuable for metabolic assays and drug sensitivity testing.
Point Mutation
CRISPR point mutation knock-in can introduce specific amino acid substitutions to dissect the catalytic activities of the kinase and phosphatase domains. This approach helps determine which activity is critical for a given phenotype.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows visualization and purification of the PFKFB complex. Tagged knock-in models are useful for studying complex assembly, localization, and interactions.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase PFKFB levels to study gain-of-function effects. Overexpression of PFKFB3 promotes glycolysis and supports tumor growth, while PFKFB4 overexpression enhances survival.
How EDITGENE Supports 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex Research
Researchers studying 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex-related genes often need to determine whether a candidate gene is causally involved in metabolic regulation, cancer, or immune responses. EDITGENE provides a comprehensive suite of CRISPR services to enable precise genetic manipulation and functional interrogation of PFKFB genes and their regulators.
Contact EDITGENE today to design your custom CRISPR model for 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex research.
Frequently Asked Questions About 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex
What is the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
It is a bifunctional enzyme complex that synthesizes and degrades fructose 2,6-bisphosphate, regulating glycolysis and gluconeogenesis.
What genes are involved in the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
The complex is encoded by the PFKFB gene family, including PFKFB1, PFKFB2, PFKFB3, and PFKFB4.
What is the function of PFKFB3?
PFKFB3 is a pro-glycolytic isoform that is upregulated by mTORC1 and supports tumor growth in tuberous sclerosis complex.
How is the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex regulated?
It is regulated by signaling pathways such as mTORC1, JAK/STAT, and estrogen receptor pathways, as well as post-translational modifications.
What diseases are associated with the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
It is implicated in cancer, metabolic disorders, rheumatoid arthritis, and vascular inflammation.
How can CRISPR be used to study the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise dissection of PFKFB gene function in metabolism and disease.
What is fructose 2,6-bisphosphate?
Fructose 2,6-bisphosphate is a metabolite that activates phosphofructokinase-1 and inhibits fructose-1,6-bisphosphatase, thereby promoting glycolysis and inhibiting gluconeogenesis.
Which PFKFB isoform is most studied in cancer?
PFKFB3 and PFKFB4 are the most studied in cancer, with PFKFB3 promoting glycolysis and PFKFB4 supporting survival.
Can PFKFB3 be targeted therapeutically?
Yes, PFKFB3 shRNA delivered by liposomes has been shown to enhance the efficacy of docetaxel in non-small cell lung cancer.
What methods are used to study the 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex?
Common methods include Seahorse metabolic assays, RNA-seq, immunoprecipitation, and CRISPR screens.
Conclusion
The 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase complex (GO:0043540) is a central regulator of glucose metabolism, controlling the balance between glycolysis and gluconeogenesis through fructose 2,6-bisphosphate. Its isoforms, encoded by PFKFB1-4, are differentially expressed and regulated, and their dysregulation contributes to cancer, metabolic disorders, and inflammatory diseases. Advances in CRISPR-based gene editing and screening technologies have enabled precise functional studies of this complex, revealing isoform-specific roles and therapeutic vulnerabilities. Continued research into the regulation and function of the PFKFB complex will likely yield new insights into metabolic diseases and cancer, and may lead to novel targeted therapies.
References
- 1. Selinger M et al.. 2022. Integrative RNA profiling of TBEV-infected neurons and astrocytes reveals potential pathogenic effectors.. Comput Struct Biotechnol J 20:2759-2777 PMID: 35685361
- 2. Wang Y et al.. 2020. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.. IUBMB Life 72(5):965-977 PMID: 31958214
- 3. Ros S et al.. 2012. Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 as an important regulator of prostate cancer cell survival.. Cancer Discov 2(4):328-43 PMID: 22576210
- 4. Dou K et al.. 2026. N6-methyladenosine modification of FZR1 mRNA positively regulates antiviral innate immunity by targeting the MAVS-TRAF3/6 axis.. Proc Natl Acad Sci U S A 123(11):e2536412123 PMID: 41805567
- 5. Dama A et al.. 2021. Estrogen Receptor Functions and Pathways at the Vascular Immune Interface.. Int J Mol Sci 22(8) PMID: 33923905
- 6. Estévez-García IO et al.. 2014. Glucose and glutamine metabolism control by APC and SCF during the G1-to-S phase transition of the cell cycle.. J Physiol Biochem 70(2):569-81 PMID: 24604252
- 7. McGarry T et al.. 2018. JAK/STAT Blockade Alters Synovial Bioenergetics, Mitochondrial Function, and Proinflammatory Mediators in Rheumatoid Arthritis.. Arthritis Rheumatol 70(12):1959-1970 PMID: 29790294
- 8. Chowdhury N et al.. 2017. Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer.. Pharm Res 34(11):2371-2384 PMID: 28875330
